<DOC>
	<DOCNO>NCT00406965</DOCNO>
	<brief_summary>This Phase II , multicenter , randomize , double blind , placebo control , multiple-dose study design evaluate efficacy , safety , tolerability subcutaneously administer HAE1 subject 12-75 year old moderate severe asthma whose symptom inadequately control moderate high-dose ICS LABA .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy HAE1 Subjects With Moderate Severe Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Signed Informed Consent Form ( ) Male female 1275 year age diagnosis allergic asthma 12 month accord standard American Thoracic Society Baseline FEV1 value ≥ 40 % ≤ 80 % predict normal value subject Demonstration ≥ 12 % increase FEV1 baseline value within 30 minute take four puff albuterol ( 90 ug/puff ) Treatment ICS dose equivalent 250500 ug fluticasone twice daily ( BID ) 8 week prior screen need regular use bronchodilator therapy Treatment stable regimen 50 ug salmeterol BID 12 ug formoterol BID least 8 week prior screen ( without asthma controller medication ) A positive radioallergosorbent test ( RAST ) one pertinent perennial seasonal allergen Total serum IgE level ≥ 20 ≤ 1500 IU/mL body weight ≥ 40 ≤ 150 kg Acceptable medical history physical examination result Demonstrated ability use MiniWright peak flow meter measurement peak expiratory flow ( PEF ) meter dose inhaler ( MDI ) administration albuterol rescue medication Willingness complete daily diary card History smoke less 10 packyears smoke ≥ 12 month For female childbearing potential , use effective method contraception screen throughout duration study participation ( e.g. , oral , mechanical , SC , surgical contraception ) Inadequately control asthma 4 week runin period demonstrate either follow : One nighttime awakening per week Asthma symptom day require rescue medication 2 day per week Active lung disease asthma Asthma exacerbation require treatment addition systemic ( oral IV ) corticosteroid increase systemic corticosteroid within 1 month prior screen runin period Significant change ( e.g. , 50 % change ) dosage inhaled corticosteroid daily dose dose schedule within 1 month prior screen visit runin period Significant medical illness asthma Treatment methotrexate , gold salt , cyclosporine , theophylline , macrolide antibiotic within 3 month prior screen runin period Treatment HAE1 Any treatment omalizumab Known hypersensitivity ingredient HAE1 formulation , trial rescue medication ( albuterol ) , related drug History acute infectious sinusitis respiratory tract infection within 1 month prior screen runin period Aspirin nonsteroidal antiinflammatory drugrelated asthma Allergy vaccination therapy &lt; 3 month stable maintenance dose prior screen Treatment oral parenteral corticosteroid within 1 month prior screen runin period Current treatment &lt; beta &gt; blocker medication ( e.g. , propranolol ) Clinically significant abnormality 12lead electrocardiogram ( ECG ) screen Abnormal chest Xray ( exclude change consistent asthma ) within 12 month prior screen Clinically significant active systemic disease ( e.g. , cancer , neoplasia , infection , hematological , renal , hepatic , coronary heart disease cardiovascular disease , endocrine gastrointestinal disease ) within 3 month screen runin period Inability unwillingness comply study procedure visit ( e.g. , spirometry , blood draw , subject diary ) History drug alcohol abuse Elevated serum IgE level reason allergy ( e.g. , parasitic infection , hyperimmunoglobulin E syndrome , WiskottAldrich syndrome , bronchopulmonary aspergillosis ) Pregnancy lactation Platelet count ≤ 110,000/mm^3 ≤ 110 x 10^9/L screen qualify runin visit Clinically significant laboratory abnormality , would limit participation study interfere interpretation study , affect subject safety , evaluation screen qualify runin visit Treatment investigational drug within 1 month screen runin period</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>